Targeted Treatments in Fragile X Syndrome
S. Jacquemont1, A. Curie2, V. des Portes3, M. G. Torrioli4, E. Berry-Kravis5, R. Hagerman6, F. J. Ramos7, K. Cornish8, Y. He9, C. Paulding9, G. Neri10, F. Gasparini11, A. Floesser12, J. Branson11, G. Bilbe11, D. Johns13 and B. Gomez-Mancilla13, (1)Medical Genetics, University Hospital of Lausanne, University of Lausanne, Lausanne, Switzerland, (2)Hospices Civils de Lyon, Université de Lyon and CNRS, Lyon, France, (3)Hospices Civils de Lyon, Université de Lyon and CNRS UMR 5230 (L2C2), Lyon, France, (4)Università Cattolica del Sacro Cuore, Cattedra di Neuropsichiatria Infantile, Rome, Italy, (5)Rush University Medical Center, Chicago, IL, (6)Fragile X Research and Treatment Center, UC Davis MIND Institute, Sacramento, CA, (7)Department of Pediatrics, University of Zaragoza Medical School,, Zaragoza, Spain, (8)School of Psychology, Psychiatry, & Psychological Medicine, Victoria, Australia, (9)Biomarker Development, Novartis Institutes for Biomedical Research, Cambridge, MA, (10)Università Cattolica del Sacro Cuore, Istituto di Genetica Medica, Rome, Italy, (11)Neuroscience Discovery, Novartis Pharma AG, Basel, Switzerland, (12)Neuroscience Clinical Sciences and Innovation, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland, (13)Neuroscience Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland